CIDP: Current Treatments and Identification of Targets for Future Specific Therapeutic Intervention

Chronic inflammatory demyelinating polyneuropathy (CIDP) is an acquired immune-mediated disorder of the peripheral nervous system. This clinically heterogeneous neurological closely related to Guillain–Barré syndrome and considered chronic counterpart that acute disease. Currently available treatments are mostly empirical; they include corticosteroids, intravenous immunoglobulins, plasma exchange immunosuppressive agents, either alone or in combination. Recent advances understanding underlying pathogenic mechanisms CIDP have brought a number novel ways possible intervention for use CIDP. review summarizes selected pre-clinical clinical findings, highlights importance using adapted animal models evaluate efficacy treatments, proposes outlines future directions ameliorate conditions patients with